Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, Dekosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. More ApoE4 Means More Amyloid in Brains of Middle-Aged
  2. St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD?
  3. Medical Foods—Fallback Option for Elusive AD Drug Status?
  4. Early ApoE4 Memory Effects, But Do You Really Want to Know?
  5. Miami: Age and Amyloid—What Has ApoE Got to Do With It?
  6. St. Louis: Imaging Preclinical AD—Can You See it Coming in the Brain?
  7. On Your “Virtual” Bike! Exercise and Exergames Bring Benefits
  8. HAI Seattle: Not Just Amyloid, Not Just PIB
  9. HAI Seattle: Biomarkers Closing in on AD Pathological Sequence?
  10. Toronto: Human Amyloid Imaging Conference Showcases a Maturing Field
  11. Phoenix: Trials in Colombia and the U.S. for Those at Highest Risk?
  12. St. Louis: ApoE—A Clearer View of its Role In AD?

Research Timeline Event

  1. ApoE4 genotype influences timing and amount of amyloid deposition in human brain